- Aktuelle Seite:
-
Home
-
Harm Reduction / Schadensminderung
- Naloxon
Spectrometric Imaging of the Brain Demonstrates the Regional Displacement of 6-Monoacetylmorphine by Naloxone.
Teklezgi BG, Pamreddy A, Ntshangase S, et al. Mass
ACS Omega. 2020;5(22):12596-12602. Published 2020 May 27. doi:10.1021/acsomega.9b03570
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288357/
Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.
Moss RB, Pryor MM, Baillie R, Kudrycki K, Friedrich C, Reed M, et al. (2020)
PLoS ONE 15(6): e0234683. https://doi.org/10.1371/journal.pone.0234683
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234683
Opioid antidote induced pulmonary edema and lung injury.
Yarlagadda K, Kim J, Kanderi T, Sendil S, Nookala VK. Opioid
Respir Med Case Rep. 2020;30:101107. Published 2020 May 29. doi:10.1016/j.rmcr.2020.101107
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287275/
Does intranasal naloxone administration increase the risk of 2019 coronavirus disease transmission?
Leong YC, Verbeek PR.
CJEM. 2020 May 12:1-2. doi: 10.1017/cem.2020.395.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251251/
Regional variation in states' naloxone accessibility laws in association with opioid overdose death rates-Observational study (STROBE compliant).
You HS, Ha J, Kang CY, et al.
Medicine (Baltimore). 2020;99(22):e20033. doi:10.1097/MD.0000000000020033
https://journals.lww.com/md-journal/FullText/2020/05290/Regional_variation_in_states__naloxone.18.aspx
Abgabe von Naloxon in Deutschland - Deutscher Bundestag Drucksache 19/18361 19. Wahlperiode 24.03.2020
Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten Dr. Wieland Schinnenburg, Michael Theurer, Grigorios Aggelidis, weiterer Abgeordneter und der Fraktion der FDP – Drucksache 19/17670 –
https://dip21.bundestag.de/dip21/btd/19/183/1918361.pdf
Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico.
Salvador, J.G., Sussman, A.L., Takeda, M.Y. et al.
Harm Reduct J 17, 31 (2020). doi.org/10.1186/s12954-020-00375-2
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-020-00375-2
FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone
Cohen BR, Mahoney KM, Baro E, et al.
N Engl J Med. 2020;382(22):2129‐2136. doi:10.1056/NEJMsa1912403
https://www.nejm.org/doi/full/10.1056/NEJMsa1912403
Intranasal versus Intramuscular/Intravenous Naloxone for Pre-hospital Opioid Overdose: A Systematic Review and Meta-analysis.
Yousefifard M, Vazirizadeh-Mahabadi MH, Neishaboori AM, Alavi SNR, Amiri M, Baratloo A, Saberian P.
Adv J Emerg Med. 2019 Nov 16;4(2):e27. doi: 10.22114/ajem.v0i0.279.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163267/
Safety of Naloxone in Opioid-Naïve Methadone Intoxicated Patients; a Case Series Study.
Shakeri SHR, Hassanian-Moghaddam H, Zamani N.
Arch Acad Emerg Med. 2020 Mar 2;8(1):e16.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130441/
Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skåne County, Sweden.
Troberg K, Isendahl P, Blomé MA, Dahlman D, Håkansson A.
BMC Psychiatry. 2020 Feb 7;20(1):49. doi: 10.1186/s12888-020-2470-3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006080/
Administration of Naloxone in a Home or Community Setting: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines [Internet].
Chao YS, Loshak H.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Dec 18.
https://www.ncbi.nlm.nih.gov/books/NBK554744/
Administration of Naloxone in a Home or Community Setting: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines [Internet].
Chao YS, Loshak H.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Dec 18.
https://www.ncbi.nlm.nih.gov/books/NBK554744/
Implementation of an Opioid Overdose and Naloxone Distribution Training in a Pharmacist Laboratory Course.
Kwon M, Moody AE, Thigpen J, Gauld A.
Am J Pharm Educ. 2020 Feb;84(2):7179. doi: 10.5688/ajpe7179.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092781/
The Prescribing and Education of Naloxone in a Large Academic Medical Center.
Miller S, Williams L, Thompson AN.
Pharmacy (Basel). 2020 Mar 5;8(1). pii: E31. doi: 10.3390/pharmacy8010031.
https://www.mdpi.com/2226-4787/8/1/31
Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland.
Buresh M, Gicquelais RE, Astemborski J, Kirk GD, Mehta SH, Genberg BL (2020)
PLoS ONE 15(3): e0230127. doi.org/10.1371/journal.pone.0230127
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230127
Pharmacological Profile of Naldemedine, a Peripherally Acting μ-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol.
Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y, Hasegawa M.
J Pharmacol Exp Ther. 2020 Mar 13. pii: jpet.119.264515. doi: 10.1124/jpet.119.264515.
http://jpet.aspetjournals.org/content/early/2020/03/13/jpet.119.264515.long
Rapid Naloxone Administration Workshop for Health Care Providers at an Academic Medical Center.
Jawa R, Luu T, Bachman M, Demers L.
MedEdPORTAL. 2020 Feb 14;16:10892. doi: 10.15766/mep_2374-8265.10892.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062540/
Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skåne County, Sweden.
Troberg K, Isendahl P, Blomé MA, Dahlman D, Håkansson A.
BMC Psychiatry. 2020 Feb 7;20(1):49. doi: 10.1186/s12888-020-2470-3.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006080/
Reversal of the effects of clonidine using naloxone.
Swift A, Wilson M.
Anaesth Rep. 2019 Mar 11;7(1):4-6. doi: 10.1002/anr3.12004.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931288/
Administration of Naloxone in a Home or Community Setting: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines [Internet].
Chao YS, Loshak H.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Dec 18.
PMID: 32134608
https://www.ncbi.nlm.nih.gov/books/NBK554744/
Risk of Seizure after Naloxone Therapy in Acute Tramadol Poisoning: A Systematic Review with Meta-Analysis.
Eizadi-Mood N, Ghandehari M, Mansourian M, Sabzghabaee AM, Samasamshariat S, Sadeghi E.
Int J Prev Med. 2019 Oct 9;10:183. doi: 10.4103/ijpvm.IJPVM_268_18.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826754/
Frankfurt/M. Verabreichung des Medikaments Naloxon als Nasenspray (Handelsname Nyxoid®) im Notfall durch idh-Mitarbeiter*innen
Mit der verschärften Lage auf dem Markt für illegale Drogen ist auch mit dem vermehrten Auftreten von Überdosierungen zu rechnen. In den Konsumräumen, Notschlafstellen, im Streetwork und im Nachtbus des Frankfurter Trägers Integrative Drogenhilfe e.V. (idh) stehen bereits Nyxoid-Nasensprays (Naloxon) als leicht zu handhabendes Notfallmedikament zur Verfügung. “Sobald wir genügend Nasensprays haben, erhalten es auch unsere anderen Angebote,“ schreibt Gabi Bescker, Geschäftsführerin bei idh.
Am 20.03.2020 hat sie dieses Informationsschreiben an ihre Mitarbeiter*innen gerichtet.
Frankkfurt idh Naloxon Anschreiben.pdf
Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program.
Katzman JG, Takeda MY, Greenberg N, Moya Balasch M, Alchbli A, Katzman WG, Salvador JG, Bhatt SR.
JAMA Netw Open. 2020 Feb 5;3(2):e200117. doi: 10.1001/jamanetworkopen.2020.0117.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2761870
Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates.
Gangal NS, Hincapie AL, Jandarov R, Frede SM, Boone JM, MacKinnon NJ, Koechlin K, DeFiore-Hyrmer J, Holthusen A, Heaton PC.
JAMA Netw Open. 2020 Jan 3;3(1):e1920310. doi: 10.1001/jamanetworkopen.2019.20310.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2759842
USA. Life-Saving Naloxone from Pharmacies - More dispensing needed despite progress (free CE)
FREE webinar featuring the U.S. Surgeon General and a CDC opioid expert. CDC - U.S. Centers for Disease Control and Prevention, Vital Signs, August 2019)
https://www.cdc.gov/vitalsigns/naloxone/
Take-home naloxone program is a priority in Iran.
Mehrpour O.
J Res Med Sci. 2019 Dec 23;24:111. doi: 10.4103/jrms.JRMS_480_19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950333/
Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review.
Moe J, Godwin J, Purssell R, O'Sullivan F, Hau JP, Purssell E, Curran J, Doyle-Waters MM, Brasher PMA, Buxton JA, Hohl CM.
CJEM. 2020 Jan 20:1-9. doi: 10.1017/cem.2019.471.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31955714
Preventing opioid overdose with peer-administered naloxone: findings from a rural state.
Hanson BL, Porter RR, Zöld AL, Terhorst-Miller H.
Harm Reduct J. 2020 Jan 9;17(1):4. doi: 10.1186/s12954-019-0352-0.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953279/
USA. Could a Naloxone Implant Have a Major Impact on the Overdose Crisis?
Researchers in Illinois are developing a novel device to rapidly and automatically administer the opioid overdose antidote naloxone. Smaller than a pacemaker, it would be implanted in a person’s body. When it detects signs of an overdose, it would release naloxone—and even place a 911 call. (Filter, USA, 28.01.2020)
https://filtermag.org/naloxone-implant/
Seite 1 von 10